speb/financial-data huggingface dataset:
ULTP.L balance_sheet (quarterly, 2026-01-31) — Total Tax Payable: 2661000.00
ULTP.L balance_sheet (quarterly, 2026-01-31) — Treasury Shares Number: 2898768.00
ULTP.L balance_sheet (quarterly, 2026-01-31) — Working Capital: 12956000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -141881100000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 55146000000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -1452800000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Amortization: 1727100000.00
ULTRACEMCO.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 2096500000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 288424921.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Basic EPS: 254.64
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 58311500000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 1205400000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Derivative Product Liabilities: 0.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 288547584.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Diluted EPS: 254.53
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 126200000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Financial Assets: 3678900000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 13422600000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 5476900000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 1287300000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 32168900000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Hedging Assets Current: 382600000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Interest Income: 1637000000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 1637000000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 94433200000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Liabilities Heldfor Sale Non Current: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 419354500000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Net Income Discontinuous Operations: 1599200000.00
ULTRACEMCO.NS cash_flow (annual, 2022-03-31) — Net Other Investing Changes: -661800000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Non Current Accrued Expenses: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 38300000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 8224200000.00
ULTRACEMCO.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Inside Changein Cash: 9014800000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 1868600000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Other Non Current Liabilities: 8000000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Other Payable: 4248700000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 17311600000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Properties: 57532300000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 39180100000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 1546100000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 1546100000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 1751800000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 80537300000.00
ULTRACEMCO.NS cash_flow (annual, 2022-03-31) — Short Term Debt Issuance: 362900000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 134600000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Tradeand Other Payables Non Current: 3034800000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Treasury Stock: 1542900000.00
ULTRACEMCO.NS balance_sheet (annual, 2022-03-31) — Work In Process: 9430200000.00
ULTRACEMCO.NS income_statement (annual, 2022-03-31) — Write Off: 0.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — +Operating Expense: 419332000000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — +Total Revenue: 623376000000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 72093000000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 38670200000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -170012900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 55219400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -987000000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Amortization: 1949200000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 2175000000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Assets Held For Sale Current: 180200000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 8500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 288326723.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Basic EPS: 175.63
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 1205400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 62874400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -62001100000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 11569600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 2886900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 3703700000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 70297700000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -10912700000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 3703700000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -9919100000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -4793000000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Change In Payable: 18686000000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -7523300000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -3369500000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 2504400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Common Stock: 2886900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 543245400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 127800000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Common Stock Payments: -1145300000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 65591400000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 128272500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Current Assets: 207429000000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 1463100000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Current Debt: 45443700000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 46906800000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 234317900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 2044300000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Depreciation: 26704900000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 28879900000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 28879900000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 26930700000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Derivative Product Liabilities: 0.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 288480570.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Diluted EPS: 175.54
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 50639600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 140600000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Dividends Received Cfi: 0.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — EBIT: 81782000000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — EBITDA: 110661900000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: -6100000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — End Cash Position: 3703700000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Financial Assets: 4424300000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 5843400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -16310000000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 6986600000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 28684000000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -1478800000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -3400000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 1738400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Goodwill: 63292600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 66947000000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 39657200000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 764502100000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Gross Profit: 495103500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Hedging Assets Current: 321800000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Interest Expense: 7619500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 7619500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Interest Income: 2724500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 2724500000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -7649400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 2827400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Inventory: 66118300000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 642253200000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -71870700000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 5843400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 127800000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 10317600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 97172600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 10106500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 53564100000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 63670600000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 8259300000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -5788200000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 8760100000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 6242100000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 477721300000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 556300000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Minority Interests: -94400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: -9139900000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: -1017500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Net Debt: 95304100000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -701600000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Income: 50639600000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 50639600000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 50734000000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Income Discontinuous Operations: 0.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 50639600000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 50639600000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 74162500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 50734000000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Interest Income: -4957300000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -4502400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 4529400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 2471100000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -4957300000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Net PPE: 594489200000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -61055800000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 2058300000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 476298400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Non Current Accrued Expenses: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 36700000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 65600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 62601100000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 16971100000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 109357400000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Normalized Income: 49747191550.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 90685100000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Operating Income: 75771500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Operating Revenue: 623376000000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 288265854.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Other Cash Adjustment Inside Changein Cash: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 18182800000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 47929500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 801800000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 3654400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 1690400000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 5502700000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 32654900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 1100000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 1497200000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 213715200000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Payable: 4623600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Properties: 1990500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 10622900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 66594000000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Other Special Charges: -328300000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Payables: 90521400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 19452800000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Pretax Income: 74162500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Properties: 59151900000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: -1390600000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: -9174800000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -76437700000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -62001100000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 44137400000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 128272500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 28879900000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 1944100000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 1944100000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -5788200000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -1145300000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 1764400000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Restructuring And Mergern Acquisition: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 90463000000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Sale Of Business: 34900000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 71935300000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 945300000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 153052500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 154790900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Share Issued: 288686345.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Short Term Debt Issuance: 2058300000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Special Income Charges: 328300000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 355800000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 543245400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 476298400000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 412091550.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Tax Provision: 23428500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.32
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 700000.00
ULTRACEMCO.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -11243100000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Total Assets: 913869600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 596809500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Total Debt: 110577400000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 543801700000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Total Expenses: 547604500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 370067900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 706440600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 135750000000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 62300000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 13664200000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 1304500000.00
ULTRACEMCO.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 1304500000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 2731000000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 420491.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Treasury Stock: 2568600000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Work In Process: 13303900000.00
ULTRACEMCO.NS balance_sheet (annual, 2023-03-31) — Working Capital: -26888900000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — +Operating Expense: 448191100000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — +Total Revenue: 698095300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 84783300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 42781600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -199842100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 55248600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -1213500000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Amortization: 1983100000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 1983100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 149000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 2600000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 288212100.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Basic EPS: 243.05
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 3703700000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 67720900000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -90055900000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 11045600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 2886900000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 5535800000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 64034900000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -10944300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 5535800000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -17115300000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -2781700000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Change In Payable: 19590000000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -4209600000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -4810500000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 1837700000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Common Stock: 2886900000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 602274800000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 179500000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: -1004100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 94677000000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 153221300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Current Assets: 231583700000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 1624500000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Current Debt: 49906100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 51530600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 269059600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 2575000000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Depreciation: 29469900000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 31453000000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 31453000000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 29469900000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Derivative Product Liabilities: 0.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 288429818.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Diluted EPS: 242.87
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 70050000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 147400000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 1600000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — EBIT: 103820000000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — EBITDA: 135273000000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: -5600000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — End Cash Position: 5535800000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Financial Assets: 4258400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 17952100000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -19256500000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 7029000000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 18919500000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -3173700000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -6700000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 1819300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Goodwill: 63454900000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 67332200000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 43995100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 856247100000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Gross Profit: 544874000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 932400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Held To Maturity Securities: 0.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Interest Expense: 9597800000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 9597800000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Interest Income: 2407500000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 2407500000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -9166800000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 1612400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Inventory: 83297400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 705258700000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -87881200000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 17952100000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 179500000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 13986200000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 103466400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 9421100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 53077800000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 62498900000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 4396300000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -10687100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 9689400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 6705700000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 530240500000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 559400000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Minority Interests: 10400000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: -1811700000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -824600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Net Debt: 97448100000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 193700000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Net Income: 70050000000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 70050000000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 70039600000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 70050000000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 70050000000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 94222200000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 70039600000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Net Interest Income: -7229300000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 1157000000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 3299100000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -6290800000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -7229300000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: -10000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Net PPE: 656405000000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -88840500000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 9589900000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 534942600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Non Current Accrued Expenses: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 35000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 49000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 64477800000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 8842900000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 132367600000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Normalized Income: 67890416180.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 108975400000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Operating Income: 96682900000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Operating Revenue: 698095300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 288193229.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 19482300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 51799200000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 1219700000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 3877300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 1512600000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 7227700000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 32642300000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 300000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 1131800000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 218024100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Payable: 4961600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Properties: 329000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 10681400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 58499100000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Other Special Charges: -585900000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Payables: 109727000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 27786800000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Pretax Income: 94222200000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Properties: 59813300000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 118900000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: -1811700000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -76293200000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -90055900000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 60493800000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 153221300000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 31453000000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 1723900000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 1723900000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -10687100000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -1004100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 1919500000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Restructuring And Mergern Acquisition: 720000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 99246000000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Sale Of Business: 0.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 77450200000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 1215400000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 174683800000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 176503100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Share Issued: 288697318.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 9589900000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Special Income Charges: -134100000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 430600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 602274800000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 534942600000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 745816180.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Tax Provision: 24182600000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.26
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 700000.00
ULTRACEMCO.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -16505200000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Total Assets: 1008020100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 655352600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Total Debt: 114029500000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 602834200000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Total Expenses: 601412400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 405185900000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 776436400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 136126300000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 39000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 19834700000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 2905400000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 2905400000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Tradeand Other Payables Non Current: 2407100000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 504089.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Treasury Stock: 3416600000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Work In Process: 14262000000.00
ULTRACEMCO.NS balance_sheet (annual, 2024-03-31) — Working Capital: -37475900000.00
ULTRACEMCO.NS income_statement (annual, 2024-03-31) — Write Off: 0.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 78076700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 43631200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Assets Held For Sale Current: 581200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 55364800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 10419700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 2887000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 1829800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 84292000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 2887000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 613650500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 64097100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 237904800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 2764200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 80369200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 83133400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 283927700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 2408400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 69470300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 126232500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 618287300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 90282800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 772869300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 55364800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 7655500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 78849600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 86505100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 1139300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 7195400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 14047600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 157389000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 618287300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 487418000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 577700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 68086600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 288203765.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 19033600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 46749400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 610763500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 56762200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 32772300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 34200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 554190200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 83200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 82462200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Payables: 97190300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 288697318.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 613650500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 487418000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 1076106000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 692500100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 169638500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 627698100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 448407900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 838201200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 164480200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 19113600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Treasury Shares Number: 493553.00
ULTRACEMCO.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: -46022900000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 126730000000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 177788300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 294185241.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 46.21
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 32038800000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 9927800000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 9927800000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 294440113.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 46.17
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 13594300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — EBIT: 21480200000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — EBITDA: 31408000000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 145749500000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 4567500000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 4567500000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Minority Interests: -40100000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Income: 13594300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 13594300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 13634400000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Income Discontinuous Operations: -100000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 13594300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 13594300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 13634400000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -4567500000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -4567500000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 31408000000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 13594300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Operating Income: 19019500000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 177788300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 2473200000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 67541100000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 16912700000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 32038800000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 9927800000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Restructuring And Mergern Acquisition: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Selling And Marketing Expense: 40360500000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Selling General And Administration: 40360500000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 3278300000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.19
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 158768800000.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2024-12-31) — Write Off: 0.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — +Operating Expense: 490121600000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 152204600000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — +Total Revenue: 749364500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 230633200000.00